{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:09:58Z","timestamp":1788854998824,"version":"build-2803163510"},"reference-count":40,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["17\/33\/03"],"award-info":[{"award-number":["17\/33\/03"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Many patients with ulcerative colitis report ongoing diarrhoea even when their disease is stable and in remission.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n MODULATE was a pragmatic, multicentre, seamless, adaptive, phase 2\/3 open-label, parallel-group, multiarm multistage randomised controlled trial.<\/jats:p>\n <\/jats:sec>\n \n Setting and participants<\/jats:title>\n People aged over 18 years with stable ulcerative colitis who had diarrhoea, recruited from secondary care sites in the United Kingdom.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n The control arm consisted of modified first-line dietary advice given to all patients with irritable bowel syndrome; the first interventional arm was amitriptyline, a tricyclic antidepressant, which at low doses slows colonic transit; the second intervention was loperamide, an antidiarrhoeal drug also thought to slow colonic transit; the third was ondansetron, an antiemetic thought to slow colonic transit; and the fourth was a diet low in fermentable oligo-, di-, and mono-saccharides and polyols, which is thought to reduce bloating and gas within the small intestine. All patients randomised to an interventional arm were to receive treatment for 6 months.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures: Primary outcome measures<\/jats:title>\n Phase 2: Improvement in diarrhoea measured using the Gastrointestinal Symptom Rating Scale-irritable bowel syndrome questionnaire at 8 weeks post randomisation: improvement defined as those reporting minor discomfort from diarrhoea or less (scoring \u2264\u20052 on the diarrhoea subscale).<\/jats:p>\n <\/jats:sec>\n \n Secondary outcome measures<\/jats:title>\n Phases 2 and 3: Measured at both 8 weeks and 6 months:<\/jats:p>\n \n \n Improvement in diarrhoea measured using the Gastrointestinal Symptom Rating Scale-irritable bowel syndrome.<\/jats:p>\n <\/jats:list-item>\n \n Blood for C-reactive protein, stool for faecal calprotectin at 6 months only, reviewing case notes for escalation of medical therapy for ulcerative colitis.<\/jats:p>\n <\/jats:list-item>\n \n Anxiety and depression, via the Hospital Anxiety and Depression Scale.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>\n \n Results<\/jats:title>\n The MODULATE trial opened in December 2021 and closed in January 2023. Of the eight secondary care sites that completed contracting, only four opened to recruitment during this time, and one person was randomised. Trial timelines coincided with the start of the COVID-19 pandemic, causing substantial delays and, ultimately, its early closure. During this time, the trial underwent two major redesign phases, enabling a fully remote participant pathway incorporating electronic consent, remote data capture, posted blood and stool sample kits for eligibility screening, delivery of the dietary intervention via telephone or video call platform, postage of trial investigational medicinal products directly to participants\u2019 homes and all trial follow-up appointments conducted via telephone. The second phase of redesign pushed the trial towards a fully decentralised model. However, this stage was not implemented due to the decision to close the trial early.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n The study was unable to recruit the necessary sample size, preventing the trial from progressing. The trial met with several challenges. The Trial Steering Committee\u2019s root cause analysis concluded that the pandemic was the leading factor in trial closure, especially regarding our ability to recruit both sites and participants.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Although the trial closed early and with insufficient participants to proceed with full statistical analysis, lessons were learnt that could potentially inform future remote trial design and decentralised participant pathways.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n MODULATE was a commissioned call in response to a priority question identified by people living with ulcerative colitis. The question remains important and unanswered; trials to address it are needed. Given the recruitment difficulties we experienced, consideration should be given to conducting these in both primary and secondary care.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 17\/33\/03.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/ghfe4871","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T08:42:36Z","timestamp":1728376956000},"page":"1-30","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Management of diarrhoea in patients with stable ulcerative colitis with low FODMAP diet, amitriptyline, ondansetron or loperamide: the MODULATE RCT"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0280-6345","authenticated-orcid":true,"given":"Lauren A","family":"Moreau","sequence":"first","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-4359","authenticated-orcid":true,"given":"Alexander Charles","family":"Ford","sequence":"additional","affiliation":[{"name":"Leeds Institute of Medical Research at St James\u2019s, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-0292","authenticated-orcid":true,"given":"Matthew James","family":"Brookes","sequence":"additional","affiliation":[{"name":"The Royal Wolverhampton NHS Trust, Wolverhampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7299-7967","authenticated-orcid":true,"given":"Sandra","family":"Graca","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-6616","authenticated-orcid":true,"given":"Elspeth","family":"Guthrie","sequence":"additional","affiliation":[{"name":"Leeds Institute of Health Sciences, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2346-9461","authenticated-orcid":true,"given":"Suzanne","family":"Hartley","sequence":"additional","affiliation":[{"name":"NHS England, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-0229","authenticated-orcid":true,"given":"Lesley","family":"Houghton","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Surgical Sciences, Leeds Institute of Medical Research at St James\u2019s, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-6319","authenticated-orcid":true,"given":"Karen","family":"Kemp","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-1961","authenticated-orcid":true,"given":"Nicholas A","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Royal Devon University Healthcare NHS Foundation Trust, UK\/University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-9183","authenticated-orcid":true,"given":"Yvonne","family":"McKenzie","sequence":"additional","affiliation":[{"name":"Digestible Nutrition, UK\/Nuffield Health, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-3416","authenticated-orcid":true,"given":"Delia","family":"Muir","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6025-6372","authenticated-orcid":true,"given":"Pei","family":"Loo Ow","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-0239","authenticated-orcid":true,"given":"Christopher","family":"Probert","sequence":"additional","affiliation":[{"name":"Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Pryde","sequence":"additional","affiliation":[{"name":"Patient and Public Engagement, UK\/Crohn\u2019s and Colitis UK Research Champion, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8220-4923","authenticated-orcid":true,"given":"Christopher","family":"Taylor","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-9923","authenticated-orcid":true,"given":"Thomas A","family":"Willis","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8839-6756","authenticated-orcid":true,"given":"Alexandra","family":"Wright-Hughes","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-0584","authenticated-orcid":true,"given":"Amanda J","family":"Farrin","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,3]]},"reference":[{"key":"key2026090807055300_ref1-bib1","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","volume":"2016","author":"Timmer","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026090807055300_ref2-bib2","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"4","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026090807055300_ref3-bib3","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"2016","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026090807055300_ref4-bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/ajg.2016.59","article-title":"Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease","volume":"111","author":"Gracie","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"key2026090807055300_ref5-bib5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cgh.2016.05.012","article-title":"Negative effects on psychological health and quality of life of genuine irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease","volume":"15","author":"Gracie","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key2026090807055300_ref6-bib6","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1097\/MIB.0000000000000984","article-title":"Ongoing symptoms in ulcerative colitis patients in remission: irritable bowel syndrome or gastrointestinal symptoms in the absence of inflammation?","volume":"23","author":"Gracie","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key2026090807055300_ref7-bib7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.12624","article-title":"Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease","volume":"39","author":"Williams","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key2026090807055300_ref8-bib8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key2026090807055300_ref9-bib9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ajg.2012.89","article-title":"A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key2026090807055300_ref10-bib10","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"key2026090807055300_ref11-bib11","doi-asserted-by":"crossref","first-page":"h701","DOI":"10.1136\/bmj.h701","article-title":"Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance","volume":"350","author":"Hookway","year":"2015","journal-title":"BMJ"},{"key":"key2026090807055300_ref12-bib12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","article-title":"A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea","volume":"63","author":"Garsed","year":"2014","journal-title":"Gut"},{"key":"key2026090807055300_ref13-bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41395-018-0222-5","article-title":"Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis","volume":"114","author":"Ford","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"key2026090807055300_ref14-bib14","article-title":"Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome","volume":"2011","author":"Ruepert","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026090807055300_ref15-bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41395-018-0084-x","article-title":"American College of Gastroenterology monograph on management of irritable bowel syndrome","volume":"113","author":"Ford","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"key2026090807055300_ref16-bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2036.1994.tb00273.x","article-title":"Influence of antidepressants on whole gut orocaecal transit times in health and irritable bowel syndrome","volume":"8","author":"Gorard","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"key2026090807055300_ref17-bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF01536922","article-title":"GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man","volume":"35","author":"Talley","year":"1990","journal-title":"Dig Dis Sci"},{"key":"key2026090807055300_ref18-bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/00365529709025060","article-title":"Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence","volume":"32","author":"Sun","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"key2026090807055300_ref19-bib19","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.3748\/wjg.v23.i18.3356","article-title":"Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease","volume":"23","author":"Pedersen","year":"2017","journal-title":"World J Gastroenterol"},{"key":"key2026090807055300_ref20-bib20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/MIB.0000000000001059","article-title":"Antidepressants in inflammatory bowel disease: a systematic review","volume":"23","author":"Macer","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key2026090807055300_ref21-bib21","first-page":"509","article-title":"Fluoxetine for maintenance of remission and to improve quality of life in patients with Crohn\u2019s disease: a pilot randomized placebo-controlled trial","volume":"11","author":"Mikocka-Walus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key2026090807055300_ref22-bib22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"},{"key":"key2026090807055300_ref23-bib23","volume-title":"Ulcerative Colitis: Management in Adults, Children and Young People","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key2026090807055300_ref24-bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS \u2013 a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"key":"key2026090807055300_ref25-bib25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"key2026090807055300_ref26-bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"key2026090807055300_ref27-bib27","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.crohns.2013.02.014","article-title":"Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion","volume":"7","author":"Rogler","year":"2013","journal-title":"J Crohns Colitis"},{"key":"key2026090807055300_ref28-bib28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/gut.2009.179804","article-title":"Association of Coloproctology for Great B, Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)","volume":"59","author":"Cairns","year":"2010","journal-title":"Gut"},{"key":"key2026090807055300_ref32-bib32","volume-title":"King\u2019s College London Low FODMAP Education Courses for Health Professionals","author":"King\u2019s College London","year":"2023"},{"key":"key2026090807055300_ref33-bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/pst.485","article-title":"Seven useful designs","volume":"11","author":"Julious","year":"2012","journal-title":"Pharm Stat"},{"key":"key2026090807055300_ref34-bib34","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial","volume":"52","author":"Probert","year":"2003","journal-title":"Gut"},{"key":"key2026090807055300_ref35-bib35","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/gut.2004.056358","article-title":"Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis","volume":"54","author":"Higgins","year":"2005","journal-title":"Gut"},{"key":"key2026090807055300_ref36-bib36","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1572-0241.2007.01094.x","article-title":"The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients","volume":"102","author":"Feagan","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"key2026090807055300_ref37-bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn\u2019s Relapse Prevention Trial Study Group","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"key":"key2026090807055300_ref38-bib38","volume-title":"MHRA Performance Data for Assessment of Clinical Trials and Established Medicines","author":"(MHRA) MaHpRA","year":"2022\u20132023 [cited 2023]"},{"key":"key2026090807055300_ref39-bib39","volume-title":"James Lind Alliance Priority Setting Partnership in Inflammatory Bowel Disease","author":"James Lind Alliance","year":"2022 [cited 2023]"},{"key":"key2026090807055300_ref40-bib40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2013.386","article-title":"Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI","volume":"109","author":"Murray","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"key2026090807055300_ref41-bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2016.09.062","article-title":"Colon hypersensitivity to distension, rather than excessive gas production, produces carbohydrate-related symptoms in individuals with irritable bowel syndrome","volume":"152","author":"Major","year":"2017","journal-title":"Gastroenterology"},{"key":"key2026090807055300_ref42-bib42","doi-asserted-by":"crossref","first-page":"e13154","DOI":"10.1111\/nmo.13154","article-title":"Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome","volume":"30","author":"O\u2019Keeffe","year":"2017","journal-title":"Neurogastroenterol Motil"},{"key":"key2026090807055300_ref43-bib43","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jada.2010.07.011","article-title":"Development and validation of a comprehensive semi-quantitative food frequency questionnaire that includes FODMAP intake and glycemic index","volume":"110","author":"Barrett","year":"2010","journal-title":"J Am Diet Assoc"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050085","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/GHFE4871\/GHFE4871.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:56:23Z","timestamp":1788854183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/published-articles\/GHFE4871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"alternative-id":["10.3310\/GHFE4871"],"URL":"https:\/\/doi.org\/10.3310\/ghfe4871","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"04-2019","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"11-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"08-2024","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}